First immune thrombocytopenia (ITP) plenary selection in 15 years underscores significant unmet need in this rare, serious autoimmune bleeding disease...
TRV045 data reflected reduced seizure burden in nonclinical models of acute epilepsy presented at American College of Neuropsychopharmacology (ACNP) Annual...
BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous...
Parkinson’s disease (PD) patients treated with NE3107 for 28 days experienced a clinically meaningful increase in motor control.Additional data presented...
Improvement in cognitive and physical functioning, measured by the CPFQ patient-rated scale, starting at week 1 and sustained over 12...
SEATTLE, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Intrinsic Medicine, Inc. (Intrinsic), a therapeutics company leveraging human milk biology to transform Gut-Brain Axis...
Brain Activate - ENERGY Gel Brain Activate - ENERGY Gel is a rapidly absorbed focus and cognitive enhancer that is...
- Mr. Fenton augments board expertise as the Company readies for Phase 1b/2 execution of lead program targeting mast cell...
PAS-003 is a first in class monoclonal antibody targeting Alpha 5 Beta 1 integrin as a treatment for amyotrophic lateral...
Novel antibody, TB006, demonstrated improvements in cognition and function and was well tolerated in a one-month Phase 1b/2 trial in...
Glen Rock, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a...
VANCOUVER, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
BOSTON and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced...
Researchers to study the potential of SCY-247 to fight Candida auris (C.auris), a multidrug-resistant pathogen named as an “urgent threat”...
Presentation highlights a novel target identified for Alzheimer’s disease using Cerevance’s proprietary NETSseq platform Cerevance’s THIK-1 targeting inhibitor, C101248, demonstrated...
AGOURA HILLS, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer...
New York, NY, and Tel Aviv, ISRAEL, Nov. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical...
Company is Opting to Increase Study Size to 400 due to Fast Enrollment PaceCARSON CITY, Nev., Nov. 29, 2022 (GLOBE...
Regulatory clearance lays key technological and regulatory foundation for BT BeaMedical’s vision of revolutionizing treatment options in neurosurgery, oncology, and...
Las Vegas, Nevada, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Founded by a team of experts with over 60 years of...